Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells

CONCLUSION: Our data suggest that the combination of decitabine with CAR T-cell therapy is an attractive novel therapeutic approach to enhance tumor-specific killing of bladder cancer. Since BID and BCL2L1 are essential determinants for the susceptibility of a wide variety of malignant cells, their targeting might be additionally suitable for combination with immunotherapies, e.g., CAR T-cells or checkpoint inhibitors in other malignancies.PMID:34868059 | PMC:PMC8637820 | DOI:10.3389/fimmu.2021.782448

Source: Cancer Control - December 6, 2021 Category: Cancer & Oncology Authors: Camilla M Grunewald Corinna Haist Carolin K önig Patrick Petzsch Arthur Bister Elfriede N ößner Constanze Wiek Kathrin Scheckenbach Karl K öhrer G ünter Niegisch Helmut Hanenberg Mich èle J Hoffmann Source Type: research